Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.

Journal of Neuro-oncology
Alicia TosoniAlba A Brandes

Abstract

Patients with recurrent or progressive low grade gliomas survive for a decade or more following diagnosis, and may be at a higher risk for treatment-related complications, such as cognitive impairment from radiotherapy. The aim of the present study was to determine in patients with progressive or recurrent low grade gliomas, the response rate and toxicity incurred by a continued schedule of temozolomide chemotherapy administered before radiation therapy, and to explore correlations between response and survival with 1p/19q deletions and MGMT promoter methylation status. Progressive radio and chemotherapy naïve low grade glioma patients with O(6)-methyl-guanine-DNA-methyl-tranferase (MGMT) promoter status evaluation were considered eligible. Chemotherapy cycles consisted of temozolomide 75 mg/m(2)/daily for 21 days every 28 days for 12 cycles. A total of 30 patients (median age 45 [range: 24.2-68.6] years) with a median KPS of 90 (range 60-90) were accrued. The overall response rate was 30% (9 partial responses); 17 patients (56.7%) had disease stabilization. The prolonged temozolomide schedule considered in the present study is followed by a high response rate; toxicity is acceptable. Further randomized trials should therefore ...Continue Reading

References

Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ G Cairncross
Jan 1, 1989·Biomedical Chromatography : BMC·R BhushanP V Mallikharjun
May 11, 2000·The New England Journal of Medicine·J A Kovacs, H Masur
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer A QuinnHenry S Friedman
Nov 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M BradaC Westbury
Nov 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A PaceC M Carapella
Jul 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K Hoang-XuanJ Y Delattre
Jul 29, 2005·Annals of Neurology·Michèle KujasJean-Yves Delattre
Feb 16, 2006·Neurology·A TosoniA A Brandes
Sep 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luigi MarianiMichael M Reinert
Dec 29, 2006·Annals of Neurology·Sibille EverhardJoëlle Thillet

❮ Previous
Next ❯

Citations

Nov 4, 2010·Nature Reviews. Neurology·T David Bourne, David Schiff
Mar 30, 2010·Expert Opinion on Pharmacotherapy·Cagatay ArslanKadri Altundag
Nov 3, 2011·Journal of Neurosurgery·Nader SanaiMitchel S Berger
Jan 2, 2015·Neurosurgical Focus·Elizabeth B ClausMargaret Wrensch
Aug 9, 2008·Journal of Neuro-oncology·Stefano Dall'oglioSergio Maluta
Jul 13, 2011·Journal of Neuro-oncology·Harsha Prasada LashkariStergios Zacharoulis
Mar 8, 2012·Journal of Neuro-oncology·Walter TaalMartin J van den Bent
Mar 7, 2015·Neurologia Medico-chirurgica·Motoo Nagane
Nov 6, 2015·Targeted Oncology·Filippo PietrantonioMaria Di Bartolomeo
Sep 1, 2016·Neuro-oncology Practice·Andrés Felipe CardonaCarmen Balaña
Nov 20, 2012·Current Opinion in Neurology·Markus Weiler, Wolfgang Wick
Nov 9, 2015·Journal of Neuro-oncology·Johan A F KoekkoekMartin J B Taphoorn
Apr 23, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark R GilbertMinesh P Mehta
Mar 23, 2012·Current Neurology and Neuroscience Reports·Herwig M StrikBart Neyns
Jul 25, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Johan A F KoekkoekMartin J B Taphoorn
Aug 24, 2012·Current Opinion in Oncology·Aurélien ViaccozFrançois Ducray
Aug 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edward G ShawMinesh P Mehta
Jan 18, 2011·Pediatric Blood & Cancer·Ben ShoftyAnat Kesler
Jul 18, 2014·Expert Opinion on Pharmacotherapy·Cagatay ArslanKadri Altundag
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark R GilbertMinesh P Mehta
Oct 24, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Wen-Bing YangHua Liang
Aug 4, 2016·Expert Review of Neurotherapeutics·Johan A F KoekkoekMartin J B Taphoorn
Aug 20, 2010·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·R SoffiettiW Wick
Mar 7, 2012·Journal of Translational Medicine·Annette Bentsen HåvikGuro Elisabeth Lind
Oct 22, 2020·Cancers·Giuseppe LombardiTamara Ius
Jan 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Santosh KesariPatrick Y Wen
Jul 30, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Enrico FranceschiAlba A Brandes
Apr 23, 2021·Pathology, Research and Practice·Enrico FranceschiAlba Ariela Brandes
Jun 8, 2021·Molecular Diagnosis & Therapy·Lidia GattoAlba Ariela Brandes
Aug 8, 2021·Cancers·Vincenzo Di NunnoAlba Ariela Brandes
Aug 18, 2021·Clinical Drug Investigation·Vincenzo Di NunnoAlba Ariela Brandes
Aug 5, 2021·Anti-cancer Drugs·Vincenzo Di NunnoAlba A Brandes

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.